Story

Intuit Shares Fall on Weak Outlook; Semtech Climbs on Strong AI Demand

ENTHMSVIIDZHZH-TWJAKOHI
Aug 25, 20262 min read
Intuit Shares Fall on Weak Outlook; Semtech Climbs on Strong AI Demand
Text size
Background

Intuit (INTU) shares fell significantly in after-hours trading Tuesday after the financial software company issued a full-year forecast that fell well short of analyst expectations. The negative reaction overshadowed positive moves from semiconductor firm Semtech (SMTC), which rose on strong earnings fueled by artificial intelligence demand.

Guidance Weighs on Software Stocks

Intuit shares plunged 9% in extended trading. The primary driver was its conservative guidance for fiscal year 2027, which projected full-year earnings per share (EPS) of $22.88–$23.12, missing Wall Street’s $27.30 consensus. The company's revenue forecast of $23.3–$23.5 billion also trailed the expected $23.74 billion, which it attributed to slower growth in its TurboTax unit and ongoing platform restructuring.

Other software companies also faced pressure:

  • nCino, Inc. (NCNO), a cloud banking platform, fell 10%. While its Q2 results were in line, its Q3 revenue guidance of $161.25–$163.25 million barely met expectations, sparking investor concerns about elongated sales cycles among its regional banking clients.
  • Zoom Video Communications (ZM) stock declined 3.5% despite a modest Q2 earnings beat and a slight increase in its full-year revenue guidance. The move suggests investors are focused on the persistent normalization of growth in its core online business.

Semtech Surges on AI-Driven Beat

Sample IUX Markets – In-articleAd

In contrast, semiconductor supplier Semtech saw its shares gain 3%. The company reported a strong second-quarter performance, with adjusted EPS of $0.71 on revenue of $341.9 million, easily beating analyst targets.

Growth was propelled by a 64% surge in its AI data center networking segment. Management also issued an optimistic Q3 outlook, projecting revenue of $405–$415 million and EPS of $1.02–$1.08, both well above consensus estimates.

Biotech Firm Spyre Plummets on Trial Results

Spyre Therapeutics (SYRE) experienced the most dramatic move, with its stock plummeting 16%. The biotechnology company announced disappointing topline results from its Phase 2 SKYWAY clinical trial for SPY072, a treatment for rheumatoid arthritis.

According to the announcement, the drug failed to meet its internal efficacy threshold to be advanced as a monotherapy, leading to a sharp sell-off from investors.

Read next

More on Stocks
Back to latest news

LATEST